Navigation Links
InterMune to Release Third Quarter 2008 Financial Results on November 6
Date:10/28/2008

BRISBANE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2008 financial results on Thursday, November 6, 2008 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 71184785. To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 71184785.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
3. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
4. InterMune to Present at Canaccord Adams Conference
5. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
6. InterMune to Present at BMO Healthcare Conference
7. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
8. InterMune to Present at Jefferies Healthcare Conference
9. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
10. InterMune to Present at Citigroup Healthcare Conference
11. InterMune to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2020)... Mass. (PRWEB) , ... August 11, 2020 , ... ... $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research ... in 2021 and 2022. The network is a consortium of academic research centers ...
(Date:8/7/2020)... (PRWEB) , ... August 06, 2020 , ... ... DNA vaccine industries, announces it has closed on the purchase of greenfield for ... in Conroe, TX and includes over 21 acres in the initial acquisition, with ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International ... only $3950. With 50 million stem cells total, patients may choose which extremities they ... works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue ...
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
Breaking Biology Technology:
(Date:8/26/2020)... ... 25, 2020 , ... Modality Solutions, a biopharmaceutical cold chain validation ... list. The list is the most prestigious ranking of the nation’s fastest-growing private companies. ... year’s list, reported three-year revenue growth of 71 percent. , The Inc. 5000 ...
(Date:8/21/2020)... ... 2020 , ... The 19th Annual Bio-IT World Conference ... informatics and IT leaders goes VIRTUAL and announces its updated event features and ... takes the leadership role of keeping our life science community connected by bringing ...
(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, ... to announce that Eric Chen and Jessica Wong have joined the company’s leadership ... Strategy, respectively. , Eric Chen heads development efforts for Alucio’s flagship product, Beacon, ...
Breaking Biology News(10 mins):